PT2418201E - Formas polimorfas de (2s)-(4e)-n-metil-5-[3-(5- isopropoxipiridin)il]-4-penten-2-amina para o tratamento de distúrbios do sistema nervoso central - Google Patents
Formas polimorfas de (2s)-(4e)-n-metil-5-[3-(5- isopropoxipiridin)il]-4-penten-2-amina para o tratamento de distúrbios do sistema nervoso central Download PDFInfo
- Publication number
- PT2418201E PT2418201E PT111675286T PT11167528T PT2418201E PT 2418201 E PT2418201 E PT 2418201E PT 111675286 T PT111675286 T PT 111675286T PT 11167528 T PT11167528 T PT 11167528T PT 2418201 E PT2418201 E PT 2418201E
- Authority
- PT
- Portugal
- Prior art keywords
- isopropoxypyridin
- penten
- hydroxybenzoate
- amine
- methyl
- Prior art date
Links
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 title 1
- 208000015114 central nervous system disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74682106P | 2006-05-09 | 2006-05-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2418201E true PT2418201E (pt) | 2014-04-14 |
Family
ID=38441430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT111675286T PT2418201E (pt) | 2006-05-09 | 2007-05-08 | Formas polimorfas de (2s)-(4e)-n-metil-5-[3-(5- isopropoxipiridin)il]-4-penten-2-amina para o tratamento de distúrbios do sistema nervoso central |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US8461344B2 (enExample) |
| EP (2) | EP2021326A1 (enExample) |
| JP (1) | JP4477097B2 (enExample) |
| KR (1) | KR20090005369A (enExample) |
| CN (1) | CN101472893A (enExample) |
| AR (1) | AR060786A1 (enExample) |
| AU (1) | AU2007249485B2 (enExample) |
| BR (1) | BRPI0709781A2 (enExample) |
| CA (1) | CA2649961A1 (enExample) |
| DK (1) | DK2418201T3 (enExample) |
| EC (1) | ECSP088876A (enExample) |
| ES (1) | ES2460919T3 (enExample) |
| HR (1) | HRP20140385T1 (enExample) |
| IL (1) | IL194833A0 (enExample) |
| MX (1) | MX2008013982A (enExample) |
| MY (1) | MY144132A (enExample) |
| NO (1) | NO20084567L (enExample) |
| NZ (1) | NZ597177A (enExample) |
| PL (1) | PL2418201T3 (enExample) |
| PT (1) | PT2418201E (enExample) |
| RS (1) | RS53286B (enExample) |
| RU (1) | RU2440984C2 (enExample) |
| SA (1) | SA07280230B1 (enExample) |
| SI (1) | SI2418201T1 (enExample) |
| TW (1) | TWI389889B (enExample) |
| UA (1) | UA96447C2 (enExample) |
| UY (1) | UY30330A1 (enExample) |
| WO (1) | WO2007134034A1 (enExample) |
| ZA (1) | ZA200809284B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7790757B2 (en) | 1998-06-16 | 2010-09-07 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
| US7459469B2 (en) | 2004-11-10 | 2008-12-02 | Targacept, Inc. | Hydroxybenzoate salts of metanicotine compounds |
| UA88792C2 (ru) * | 2004-11-10 | 2009-11-25 | Таргасепт, Інк. | Гидроксибензоатные соли метаникотиновых соединений |
| CN101528698A (zh) | 2006-05-09 | 2009-09-09 | 阿斯利康公司 | (2s)-(4e)-n-甲基-5-[3-(5-异丙氧基吡啶)基]-4-戊烯-2-胺的盐形式 |
| TWI389889B (zh) | 2006-05-09 | 2013-03-21 | Targacept Inc | （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型 |
| TW200829244A (en) * | 2006-09-15 | 2008-07-16 | Astrazeneca Ab | Therapeutic combinations 482 |
| WO2008091592A1 (en) * | 2007-01-22 | 2008-07-31 | Targacept, Inc. | Intranasal, buccal, and sublingual administration of metanicotine analogs |
| KR20100052490A (ko) * | 2007-07-31 | 2010-05-19 | 타가셉트 인코포레이티드 | (2ｓ)-(4ｅ)-ｎ-메틸-5-(3-(5-이소프로폭시피리딘)일)-4-펜텐-2-아민의 경피투여 |
| CN102065845A (zh) * | 2008-06-11 | 2011-05-18 | 阿斯利康(瑞典)有限公司 | 含有(2s)-(4e)-n-甲基-5-(5-异丙氧基吡啶-3-基)-戊-4-烯-2-胺的舌下组合物 |
| WO2010080757A2 (en) * | 2009-01-07 | 2010-07-15 | Astrazeneca Ab | Combinations with an alpha-4beta-2 nicotinic agonist |
| FR2959107B1 (fr) | 2010-04-23 | 2015-03-27 | Oreal | Unite d'application d'un produit cosmetique |
| CN103180277A (zh) | 2010-05-20 | 2013-06-26 | 塔格塞普特股份有限公司 | 制备芳基取代的烯属胺的新方法 |
| WO2013184732A1 (en) * | 2012-06-06 | 2013-12-12 | Targacept, Inc. | Crystalline (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]4-penten-2-amine 1,5-naphthalenedisulfonate |
| KR101579904B1 (ko) | 2014-09-05 | 2016-01-05 | 동신대학교산학협력단 | 마스카라 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4192946A (en) | 1978-06-29 | 1980-03-11 | Ciba-Geigy Corporation | Process for producing 3-hydroxy-5-halopyridines |
| DE3148651A1 (de) | 1981-12-09 | 1983-07-21 | Henkel Kgaa | "haarfaerbemittel, enthaltend 5-halo-2,3-pyridindiole als kupplerkomponente" |
| US4582823A (en) | 1984-08-15 | 1986-04-15 | Warner-Lambert Company | Method for treating schizophrenia and medicaments therefor |
| WO1989000158A1 (en) | 1987-07-02 | 1989-01-12 | Pfizer Inc. | Bridged-diazabicycloalkyl quinolone carboxylic acids and esters |
| IT1226727B (it) | 1988-07-29 | 1991-02-05 | Simes | Farmaci precursori della dopamina. |
| US4922901A (en) | 1988-09-08 | 1990-05-08 | R. J. Reynolds Tobacco Company | Drug delivery articles utilizing electrical energy |
| ATE118216T1 (de) | 1989-04-20 | 1995-02-15 | Zambon Spa | Dopamin-medikament-vorstufe. |
| US5187166A (en) | 1990-07-31 | 1993-02-16 | Nisshin Flour Milling Co., Ltd. | Azabicyclo derivatives and their use as antiemetics |
| AU9171791A (en) | 1990-12-27 | 1992-08-17 | Abbott Laboratories | N-protected aminoalkylaldehydes |
| DE69213559T2 (de) | 1991-05-30 | 1997-02-27 | Mitsui Toatsu Chemicals | Tetravinylpyrazine-Verbindung, Verfahren zur Herstellung derselben und elektrolumineszentes Element und damit hergesteller nichtlinearer optischer Stoff |
| US5212188A (en) | 1992-03-02 | 1993-05-18 | R. J. Reynolds Tabacco Company | Method for treatment of neurodegenerative diseases |
| IL107184A (en) | 1992-10-09 | 1997-08-14 | Abbott Lab | Heterocyclic ether compounds that enhance cognitive function |
| US5852041A (en) | 1993-04-07 | 1998-12-22 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acethylcholine receptors |
| US5493026A (en) | 1993-10-25 | 1996-02-20 | Organix, Inc. | Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders |
| IT1274018B (it) | 1994-02-23 | 1997-07-14 | Riace Ets | Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica |
| CA2192975C (en) | 1994-06-14 | 1999-09-21 | Anton F. Fliri | Benzimidazolone derivatives |
| GB2295387A (en) | 1994-11-23 | 1996-05-29 | Glaxo Inc | Quinazoline antagonists of alpha 1c adrenergic receptors |
| US5604231A (en) | 1995-01-06 | 1997-02-18 | Smith; Carr J. | Pharmaceutical compositions for prevention and treatment of ulcerative colitis |
| US5597919A (en) | 1995-01-06 | 1997-01-28 | Dull; Gary M. | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
| US5616707A (en) | 1995-01-06 | 1997-04-01 | Crooks; Peter A. | Compounds which are useful for prevention and treatment of central nervous system disorders |
| US5585388A (en) | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| US5583140A (en) | 1995-05-17 | 1996-12-10 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of central nervous system disorders |
| IL118279A (en) | 1995-06-07 | 2006-10-05 | Abbott Lab | Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission |
| US5616716A (en) | 1996-01-06 | 1997-04-01 | Dull; Gary M. | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds |
| AT403803B (de) | 1996-04-19 | 1998-05-25 | Sanochemia Ltd | Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln |
| US5663356A (en) | 1996-04-23 | 1997-09-02 | Ruecroft; Graham | Method for preparation of aryl substituted alefinic secondary amino compounds |
| US6979695B2 (en) | 1996-04-23 | 2005-12-27 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
| PT900200E (pt) | 1996-04-23 | 2009-02-26 | Targacept Inc | Composições farmacêuticas para prevenção e tratamento de perturbações do sitema nervoso central |
| US20020052497A1 (en) | 2000-03-09 | 2002-05-02 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
| US5726189A (en) | 1996-05-03 | 1998-03-10 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes |
| US5861423A (en) | 1997-02-21 | 1999-01-19 | Caldwell; William Scott | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
| US5811442A (en) | 1997-02-21 | 1998-09-22 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow |
| EP0983249B1 (en) | 1997-05-08 | 2002-03-13 | Pfizer Products Inc. | Processes and intermediates for preparing substituted indazole derivatives |
| DK1027336T3 (da) | 1997-10-27 | 2005-01-24 | Neurosearch As | Heteroaryldiazacycloalkaner, deres fremstilling og anvendelse |
| US6632823B1 (en) | 1997-12-22 | 2003-10-14 | Merck & Co., Inc. | Substituted pyridine compounds useful as modulators of acetylcholine receptors |
| PT1086082E (pt) | 1998-06-16 | 2005-01-31 | Targacept Inc | Aminas olefinicas substituidas com arilo e seu uso como agonistas de receptores colinergicos |
| US6232316B1 (en) | 1998-06-16 | 2001-05-15 | Targacept, Inc. | Methods for treatment of CNS disorders |
| US6218383B1 (en) | 1998-08-07 | 2001-04-17 | Targacept, Inc. | Pharmaceutical compositions for the prevention and treatment of central nervous system disorders |
| US6337351B1 (en) | 1998-10-22 | 2002-01-08 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
| US6953855B2 (en) | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| FR2788982B1 (fr) | 1999-02-02 | 2002-08-02 | Synthelabo | Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique |
| CA2376061A1 (en) | 1999-06-07 | 2000-12-14 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
| GB9922271D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Formulation |
| US6506769B2 (en) | 1999-10-06 | 2003-01-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| EP1274433A1 (en) | 2000-04-13 | 2003-01-15 | Innovata Biomed Limited | Medicaments for treating respiratory disorders comprising formoterol and fluticasone |
| US6743812B1 (en) | 2000-07-14 | 2004-06-01 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
| US6432954B1 (en) | 2000-07-14 | 2002-08-13 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
| CA2442114C (en) | 2001-03-29 | 2011-06-21 | Eli Lilly And Company | N-(2-arylethyl)benzylamines as antagonists of the 5-ht6 receptor |
| GB2381750A (en) | 2001-10-10 | 2003-05-14 | Inspire Pharmaceuticals Inc | Treatment for enhancing joint lubrication |
| US7067261B2 (en) | 2001-12-14 | 2006-06-27 | Targacept, Inc. | Methods and compositions for treatment of central nervous system disorders |
| AU2003226094A1 (en) | 2002-03-27 | 2003-10-13 | Smithkline Beecham Corporation | Compounds and methods |
| US20040044023A1 (en) | 2002-08-30 | 2004-03-04 | Marc Cantillon | Compositions and methods for treating or preventing memory impairment |
| US20070191815A1 (en) | 2004-09-13 | 2007-08-16 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery |
| US20050203130A1 (en) | 2003-12-02 | 2005-09-15 | Erik Buntinx | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| BRPI0418092A (pt) | 2003-12-23 | 2007-04-17 | Pfizer Prod Inc | combinação terapêutica para melhora cognitiva e transtornos psicóticos |
| US20050171088A1 (en) | 2004-01-30 | 2005-08-04 | Astrazeneca Ab | Treatment of psychoses with dibenzothiazepine antipsychotic |
| AU2004319105A1 (en) | 2004-03-29 | 2005-11-10 | Mediquest Therapeutics, Inc. | Polyamine analogs that activate antizyme frameshifting |
| JP4148199B2 (ja) | 2004-07-30 | 2008-09-10 | 松下電工株式会社 | 電気かみそり |
| US7537590B2 (en) | 2004-07-30 | 2009-05-26 | Microchips, Inc. | Multi-reservoir device for transdermal drug delivery and sensing |
| US7459469B2 (en) * | 2004-11-10 | 2008-12-02 | Targacept, Inc. | Hydroxybenzoate salts of metanicotine compounds |
| UA88792C2 (ru) * | 2004-11-10 | 2009-11-25 | Таргасепт, Інк. | Гидроксибензоатные соли метаникотиновых соединений |
| TWI389889B (zh) | 2006-05-09 | 2013-03-21 | Targacept Inc | （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型 |
| CN101528698A (zh) | 2006-05-09 | 2009-09-09 | 阿斯利康公司 | (2s)-(4e)-n-甲基-5-[3-(5-异丙氧基吡啶)基]-4-戊烯-2-胺的盐形式 |
| WO2007147014A2 (en) | 2006-06-13 | 2007-12-21 | Fmc Biopolymer As | Method and systems for using biopolymer-based beads and hydrogels |
| TW200829244A (en) | 2006-09-15 | 2008-07-16 | Astrazeneca Ab | Therapeutic combinations 482 |
| US20080167286A1 (en) | 2006-12-12 | 2008-07-10 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
| WO2008091592A1 (en) | 2007-01-22 | 2008-07-31 | Targacept, Inc. | Intranasal, buccal, and sublingual administration of metanicotine analogs |
-
2007
- 2007-04-27 TW TW096115162A patent/TWI389889B/zh not_active IP Right Cessation
- 2007-05-07 UY UY30330A patent/UY30330A1/es not_active Application Discontinuation
- 2007-05-07 AR ARP070101972A patent/AR060786A1/es not_active Application Discontinuation
- 2007-05-08 RU RU2008148325/04A patent/RU2440984C2/ru not_active IP Right Cessation
- 2007-05-08 EP EP07783431A patent/EP2021326A1/en not_active Withdrawn
- 2007-05-08 RS RS20140212A patent/RS53286B/sr unknown
- 2007-05-08 PL PL11167528T patent/PL2418201T3/pl unknown
- 2007-05-08 JP JP2009503340A patent/JP4477097B2/ja not_active Expired - Fee Related
- 2007-05-08 NZ NZ597177A patent/NZ597177A/xx not_active IP Right Cessation
- 2007-05-08 MY MYPI20084443A patent/MY144132A/en unknown
- 2007-05-08 US US11/745,682 patent/US8461344B2/en not_active Expired - Fee Related
- 2007-05-08 EP EP11167528.6A patent/EP2418201B1/en active Active
- 2007-05-08 CN CNA2007800168072A patent/CN101472893A/zh active Pending
- 2007-05-08 CA CA002649961A patent/CA2649961A1/en not_active Abandoned
- 2007-05-08 MX MX2008013982A patent/MX2008013982A/es active IP Right Grant
- 2007-05-08 AU AU2007249485A patent/AU2007249485B2/en not_active Ceased
- 2007-05-08 BR BRPI0709781-6A patent/BRPI0709781A2/pt not_active IP Right Cessation
- 2007-05-08 SI SI200731433T patent/SI2418201T1/sl unknown
- 2007-05-08 WO PCT/US2007/068446 patent/WO2007134034A1/en not_active Ceased
- 2007-05-08 SA SA07280230A patent/SA07280230B1/ar unknown
- 2007-05-08 ES ES11167528.6T patent/ES2460919T3/es active Active
- 2007-05-08 DK DK11167528.6T patent/DK2418201T3/da active
- 2007-05-08 KR KR1020087027218A patent/KR20090005369A/ko not_active Abandoned
- 2007-05-08 PT PT111675286T patent/PT2418201E/pt unknown
- 2007-08-05 UA UAA200814135A patent/UA96447C2/ru unknown
-
2008
- 2008-10-22 IL IL194833A patent/IL194833A0/en unknown
- 2008-10-29 ZA ZA200809284A patent/ZA200809284B/xx unknown
- 2008-10-30 NO NO20084567A patent/NO20084567L/no not_active Application Discontinuation
- 2008-11-07 EC EC2008008876A patent/ECSP088876A/es unknown
-
2009
- 2009-10-29 US US12/608,450 patent/US20100048643A1/en not_active Abandoned
-
2013
- 2013-05-14 US US13/893,408 patent/US20130310425A1/en not_active Abandoned
-
2014
- 2014-04-28 HR HRP20140385TT patent/HRP20140385T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2418201T3 (pl) | Polimorficzne postaci p-hydroksybeznoesanu (2S)-(4E)-N-metylo-5-[3-(5-izopropoksypirydyn)ylo]-4-penteno-2-aminy do leczenia zaburzeń ośrodkowego układu nerwowego | |
| ZA200706791B (en) | Isoxazole combretasin derivatives for the treatment of disorders | |
| EP1976377A4 (en) | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | |
| PT1833799E (pt) | Derivados de 3-fenil-pirazole como moduladores do receptor 5-ht2a de serotonina úteis no tratamento de desordens que lhe estão relacionadas | |
| EP1983972A4 (en) | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | |
| ZA200808963B (en) | Compounds for the treatment of metabolic disorders | |
| IL178648A0 (en) | Substituted morpholine compounds for the treatment of central nervous system disorders | |
| IL192852A0 (en) | Compounds for the treatment of metabolic disorders | |
| IL179609A0 (en) | Imidazole variants as modulators of gaba receptor for the treatment of gi disorders | |
| IL198912A0 (en) | Isosorbide mononitrate derivatives for the treatment of intestinal disorders | |
| ZA200805159B (en) | Imidazole derivatives for the treatment of gastrointestinal disorders | |
| IL197695A0 (en) | 3-amino-pyridine derivatives for the treatment of metabolic disorders | |
| PL1841433T3 (pl) | Kompozycja do leczenia zaburzeń ośrodkowego układu nerwowego | |
| IL195392A0 (en) | Compounds for the treatment of metabolic disorders | |
| IL192851A0 (en) | Compounds for the treatment of metabolic disorders | |
| IL198432A0 (en) | 2-alkyl-indazole compounds for the treatment of certain cns-related disorders | |
| HK1128025A (en) | Polymorph forms of (2s) - (4e) -n-methyl-5- (3-isopropoxypyridin) yl]-4-penten-2-amine for the treatment of central nervous system disorders | |
| IL192982A0 (en) | Compounds for the treatment of metabolic disorders | |
| HK1122187A (en) | Compounds for the treatment of metabolic disorders | |
| HK1124246A (en) | Compounds for the treatment of metabolic disorders | |
| HK1120724A (en) | Compounds for the treatment of metabolic disorders | |
| HK1124486A (en) | Compounds for the treatment of metabolic disorders | |
| HK1121917A (en) | Compounds for the treatment of metabolic disorders | |
| HK1121935A (en) | Compounds for the treatment of metabolic disorders | |
| GB0724947D0 (en) | Composition for the treatment of psychiatric disorders |